This is a randomized, open-label, multicenter, phase III study comparing anthracyclines
followed by taxane to anthracyclines followed by taxane plus carboplatin as (neo)adjuvant
therapy in patients with triple-negative breast cancer.
Patients with stage II/III operable triple-negative breast cancer are eligible. Patients who
need adjuvant chemotherapy after breast surgery as well as patients who need neoadjuvant
chemotherapy for TNBC are eligible.
Breast Cancer Diagnosis,
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.